Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...

Casgevy has little competition to speak of ... It might go after some label expansions later, but it will be years before nex-z generates strong sales. So, even if the company aces late-stage ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

However, Casgevy's potential is enormous ... 50 ongoing clinical trials for brand-new medicines and others seeking label expansions. Third, Amgen is an excellent dividend stock.

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy ... While Journavx has a broad label to treat patients with moderate to ...

Vertex's Casgevy, a gene-editing treatment for two ... and its deep pipeline that will lead to plenty of approvals and label expansions, the drugmaker has strong long-term prospects.